The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

GSK PLC closed 11.69% short of its 52-week high of £16.79, which the company achieved on September 9th.

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares of GSK PLC GSK inched up 0.98% to £14.39 Monday, on what proved to be an all-around positive trading session for the ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Topline Pharmaceutical heavyweight GSK on Wednesday said it had settled four lawsuits in the U.S. that claimed its popular heartburn drug Zantac causes cancer, averting a trial due to start in ...

Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse ...

GSK does have some important weaknesses as an investment vehicle, however. Chief among them is the lack of a clear-cut all-star in areas like cancer, rare diseases, or metabolic disorders.

GSK shares rose around 3% during early trading in London. The boost comes after the company said it expects sales for 2023 to rise between 12% to 13%, up from earlier predictions topping out at 10%.